Preliminary studies suggest that inhibition of fibroblast growth factor receptors (FGFR) 1, 2, 3, and 4 may be a promising approach for the treatment of bladder cancers and other cancers that harbor FGFR alterations.
Researchers at the University of North Carolina School of Medicine, Chapel Hill, have identified a discrete set of genes that segregate high-grade bladder cancer into two distinct subtypes—basal-like and luminal—each of which appears to have its own molecular characteristics and outcome. The authors also found that the two subtypes share many of the characteristics seen in basal and luminal breast cancer subtypes, a discovery with clinical implications.
Researchers from the National Institutes of Health have identified new potential therapeutic targets for muscle-invasive bladder cancer, including important genes and pathways that are disrupted in the disease.
Mayo Clinic researchers have found amplification of HER2, a known driver of some breast cancers, in micropapillary urothelial carcinoma and have shown that the presence of HER2 amplification is associated with particularly aggressive tumors.
Standard and reduced high-dose volume radiation therapy for muscle-invasive bladder cancer provide similar tumor control and decreased late toxicity when compared to surgery, say the authors of a study from the United Kingdom.
The latest products and services from Cook Medical, American Medical Systems, Dialog Medical, Astellas Pharma U.S., Giffen Solutions, the Société Internationale d’Urologie, Merck Consumer Care, and the Bladder Cancer Advocacy Network.